Awaiting development: Guidance and quality standards

Showing 171 to 180 of 332

Guidance and quality standards awaiting development
Title	Type
Lutetium with androgen deprivation therapy and receptor pathway inhibitors for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]	Technology appraisal guidance
Managing symptoms with an uncertain cause	Quality standard
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]	Technology appraisal guidance
Mavorixafor for treating WHIM syndrome [ID3946]	Technology appraisal guidance
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver	Interventional procedures guidance
Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease ID1237	Technology appraisal guidance
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Health technology evaluation
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]	Technology appraisal guidance
Middle meningeal artery embolisation for chronic subdural haematomas	Interventional procedures guidance
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400]	Technology appraisal guidance